Search PubMed⌕ Search

Biomedical subjects

M Peeters

Publications and source records attributed to M Peeters.

225 records · Page 13Linked to original sources

Diagnostic approach to IBD.

Inflammatory bowel disease, with Crohn's disease and ulcerative colitis as the two main disorders, is a heterogeneous group of disorders of unknown etiology. Clinical initial presentation is sometimes misleading and causing diagnostic delay which may be important. Identification of subgroups of patients on the basis of genetic, immunologic and clinical markers will be important for exact diagnosis, but also for new drug trials. The current diagnosis depends on clinical, radiographic, endoscopic and laboratory data. The introduction of serological markers such as pANCA and ASCA will allow an increase in the diagnostic accuracy at initial diagnosis of inflammatory bowel disease and may play a role in defining subgroups of the disease.

Barium Sulfate↗

Metastatic follicular dendritic cell sarcoma of the stomach: a case report and review of the literature.

Follicular dendritic cell (FDC) sarcomas are rare tumours, typically seen in lymph nodes. However, in about one third of the reported cases, a FDC sarcoma presents as an extranodal mass. Involvement of the gastrointestinal tract is extremely rare, and only 3 cases have been described to date. We report on a 40-year-old female patient with a follicular dendritic cell sarcoma located in the stomach and the presence of a metastasis in the liver at the time of diagnosis. Severe asthenia, nausea, back pain and loss of weight were the presenting symptoms. A CT scan of the abdomen and an upper gastrointestinal endoscopy revealed a tumour mass in the stomach. The diagnosis of a FDC sarcoma was made on histological and immunohistochemical findings. We report the second case of a FDC sarcoma presenting in the stomach. Due to its rarity, a FDC sarcoma seldom enters the differential diagnosis of spindle cells neoplasms of the gastrointestinal tract. Complete surgical resection is the treatment of choice for FDC sarcoma.

Adult↗

[Infantile psychosis, pseudo-Alzheimer syndrome, and trisomy 21. A trial of treatment with folinic acid: preliminary report].

Trisomy 21 produces excess sensibility to methotrexate (dihydrofolate reductase inhibitor). A trial of medication with folinic acid (5-formyl-tetrahydrofolate) was realized on 39 trisomic 21 patients. 30 of them were affected by severe infantile psychosis and the other 9 were affected by a severe Alzheimer-like regression. On 69 assays, 37 were favorable and 32 were null. A dose/effect correlation was highly significant. It is proposed that a systematic investigation of the effects of folinic acid (associated or not with monocarbon precursors) be studied in cases of trisomy 21 complicated by precocious psychosis or severe secondary regression.

Adolescent↗

[Development and evaluation of screening algorithms for sexually transmitted diseases in pregnant women at Libreville, Gabon].

The struggle against sexually transmitted diseases (STD) constitutes a priority of public health in developing countries: STD cause complications, particularly in pregnant women, and facilitate the transmission of HIV. One of the strategies in the struggle against STD is the diagnosis and the early treatment of these infections. The STD, and in particular infections of Neisseria gonorrhea and Chlamydia trachomatis, are difficult to diagnose in women without complementary analyses, which primary health care may not be able to supply. Health care provided to patients could be standardized and improved by considering the signs and symptoms. We studied the prevalence and risk factors of STD among 192 pregnant women consulting the health clinic in Libreville, Gabon, in September 1993. The prevalence of STD was high (13.5% rate of cervical infection with gonorrhea or Chlamydia trachomatis). We then evaluated the different diagnostic strategies or algorithms. Regardless of the type of examination (medical interview, simple clinical examination or examination with a speculum), the use of scores integrating risk factors, the clinical signs and symptoms outperformed hierarchical algorithms. This approach was more sensitive and specific and easy to perform. Use of this method may enable more effective screening of STD and also avoid most maternal and perinatal complications.

Adolescent↗

The 1998 national Belgian consensus meeting on HP-related diseases: an extensive summary. The HP Belgian contact group organized in CHU Brugmann, Brussels.

"HP testing must be regarded as ONE of the important elements of the proper diagnostic work-up of a DISEASE, managed in close cooperation between GP's and specialists": that's the key message of the national consensus meeting held in CHU Brugmann on February 6th and 7th 1998. HP testing (usually by 2 direct methods: RUT-histology) and eradication treatment (ER), in infected patients, are strongly recommended in: 1. Past or current GDU (absolute indication), regardless of activity, complication(s), NSAID intake; 2. Low-grade MALT Lymphomas (Stage IE1) unequivocally diagnosed, managed and followed-up in specialised centers; 3. Post endoscopic resection of EGC. ER is advisable in HP carriers with a family history of gastric cancer. Chronic atrophic-, lymphocytic-, giant folds gastritis and hyperplastic polyps are acceptable indications for ER as well as scheduled long-term NSAID treatment in individuals with known HP status. Systematic ER in HP+ patients with fully investigated NUD is not indicated but could be considered in individual patients. Extra alimentary disorders and auto immune gastritis are no indication and there was no consensus for a "test and treat" policy in patients under 45 yrs old without alarm symptoms. Systematic screening of asymptomatic individuals is not recommended. A correct monitoring of eradication after treatment is recommended, mainly by UBT. In severe or refractory PUD, symptom recurrence and follow-up of EGC and Maltomas, endoscopic follow-up with HP testing is mandatory. The recommended first line treatment course (except known allergy or intolerance) is PPI full dose bid, Clarithromycin 500 mg bid Amoxycillin 1000 mg bid (7 days minimal 10 days maximal). RBC-based schemes must be locally validated and quadruple therapy is proposed when retreatment is needed. Culture, optional after the first treatment failure, is strongly recommended after a second failure. Overall, ER therapies are safe and neither the decreased efficacy of acid-lowering drugs, nor the possible increased risk of peptic oesophagitis are considered as contra-indications to eradicate. ER is cost-effective and cost-beneficial in PUD and adjusted number of pills delivered would cut costs. No clear economic data are currently available for a potential benefit of ER in GC prevention or NUD management. A national monitoring of HP resistance (Macrolides and Imidazoles) must be organized by specialised centers.

Gastrointestinal Diseases↗

Urea breath test: a diagnostic tool in the management of Helicobacter pylori-related gastrointestinal diseases.

UNLABELLED: The urea breath test (UBT) is generally considered as a simple, non-invasive and accurate test to demonstrate Helicobacter pylori (H. pylori) infection. The principle of the test is simple. The orally given urea, isotopically labelled with 14C or 13C, is hydrolysed by the enzyme urease of H. pylori and *CO2 is expired in breath. Although the radiation exposure is negligible (3*10(-6) Sv), the test with the stable isotope 13C should be preferred. Since the first description of the test in 1987 many refinements have been described. Most studies reported sensitivity and specificity figures between 95-100% for both. A uniform test protocol with regard to the test meal, the appropriate 13C-urea dose, the number of breath samples to be taken, ... would be ideal. But today, it is better to strive for a validation and a determination of cut off values for each protocol as such. The main indication for UBT is the confirmation of successful eradication. To avoid false negative results, testing should be performed 4 to 6 weeks after the end of treatment and 5 days after the end of acid suppressive drugs. The test is also an ideal tool to check for infection when an ulcer is found at endoscopy, but biopsy specimens can't be taken because of anticoagulant treatment. Mostly serology is the first choice to perform epidemiological studies, but UBT is a good alternative and moreover it gives an idea of the presence of active infection. The role of non-invasive tests, i.e. UBT and serology, in primary diagnosis of H. pylori is more controversial. Questions such as who will perform the test (general practitioner or gastroenterologist), what is the age limit, how to organise the follow up, what is the cost-benefit, ... still remain. All these questions need a further evaluation in terms of its influence upon clinical decision making not only in general, but also more specific for the Belgian situation. IN CONCLUSION: 1. The 13C-urea breath test is a very accurate, non-invasive test to diagnose gastric H. pylori colonisation in adults and children. 2. If local protocols are validated and appropriate cut off values are determined, general standardisation of methodology isn't necessary. 3. The 13C-urea breath test is the ideal diagnostic tool to monitor eradication therapy in patients with complicated duodenal ulcers, gastric ulcers, Malt lymphomas, poor compliance and to perform large epidemiological studies. 4. The role of the 13C-urea breath test in the clinical decision making prior endoscopy remains controversial.

Adult↗